• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
EXFORGE HCT Drug Profile, 2024: EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) drug patents, FDA exclusivity, litigation, drug pric

EXFORGE HCT Drug Profile, 2024: EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) drug patents, FDA exclusivity, litigation, drug pric

Paperback

Series: Drugpatentwatch Business Intelligence Reports

Medical Reference

Currently unavailable to order

ISBN13: 9798875596261
Publisher: Independently Published
Published: Jan 9 2024
Pages: 50
Weight: 0.31
Height: 0.10 Width: 8.50 Depth: 11.00
Language: English
EXFORGE HCT Drug Profile, 2024

This report focuses on EXFORGE HCT and covers the following critical aspects of this drug:

  • United States patents
  • Expired United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Finished product suppliers
FREE UPDATE: Send your receipt to DrugPatentWatch within 30 days for a free updat

Also in

Medical Reference